CRA’s Rebel Curd represented a large medical device company at IRS Appeals after a drawn-out field audit handled by the taxpayer. The issue related to the return earned by the US distribution operations. The matter resolved at Appeals with zero adjustment to the taxpayer’s tax return position. With CRA’s principled economic analyses based on a detailed mapping of functions and risks to the comparability criteria, statistical analysis of market returns, and the use of primary and secondary profit-level indicators supported the client’s tax return position so solidly that Appeals found that no adjustment was required.
Drug pricing rules and tariffs reshape transfer pricing for IP
In the article “Drug Pricing Rules and Tariffs Reshape Transfer Pricing for IP,” published in Bloomberg Tax, CRA’s Transfer Pricing experts Robin Hart and ...